As the U.S. stock market navigates a period of volatility, with major indices like the Nasdaq retreating from record highs amid anticipation of key economic data releases, investors are closely watching for signs that could influence future monetary policy decisions. In this climate, high-growth tech stocks in the United States remain a focal point for many investors seeking opportunities in sectors poised to benefit from technological advancements and innovation.
Name
Revenue Growth
Earnings Growth
Growth Rating
ACADIA Pharmaceuticals
10.87%
25.66%
★★★★★☆
ADMA Biologics
20.61%
23.25%
★★★★★☆
Palantir Technologies
25.38%
32.02%
★★★★★★
Circle Internet Group
30.80%
60.66%
★★★★★★
Workday
11.38%
29.97%
★★★★★☆
Mereo BioPharma Group
51.11%
57.42%
★★★★★★
OS Therapies
38.35%
16.51%
★★★★★☆
Vanda Pharmaceuticals
22.66%
57.41%
★★★★★☆
Gorilla Technology Group
27.85%
105.48%
★★★★★☆
Aldeyra Therapeutics
49.14%
72.47%
★★★★★☆
Click here to see the full list of 66 stocks from our US High Growth Tech and AI Stocks screener.
Underneath we present a selection of stocks filtered out by our screen.
Simply Wall St Growth Rating: ★★★★★☆
Overview: Protagonist Therapeutics, Inc. is a biopharmaceutical company focused on developing peptide therapeutics for hematology and blood disorders, as well as inflammatory and immunomodulatory diseases, with a market cap of $3.18 billion.
Operations: Protagonist Therapeutics generates revenue primarily from its biotechnology segment, specifically focusing on startups, amounting to $209.18 million. The company’s efforts are concentrated on developing peptide therapeutics for specific medical conditions.
Protagonist Therapeutics, despite a challenging year with a net loss widening to $46.43 million from a prior net income of $176.72 million, continues to invest in groundbreaking research, particularly in the treatment of polycythemia vera as demonstrated by their successful Phase 3 VERIFY study. This focus on specialized biotech solutions underscores its potential in an industry where innovation directly correlates with market success. The company’s significant R&D investments are aimed at pioneering treatments that address unmet medical needs, indicating a strategic push towards securing a strong position within the biotech sector. While recent financial figures show volatility, Protagonist’s aggressive growth strategy in R&D could set them apart if their pipeline products achieve commercial success.
Story Continues
PTGX Revenue and Expenses Breakdown as at Aug 2025
Simply Wall St Growth Rating: ★★★★★★
Overview: Palantir Technologies Inc. develops software platforms for intelligence and counterterrorism operations globally, with a market cap of $443.53 billion.
Operations: The company generates revenue primarily through its two main segments: Commercial, contributing $1.54 billion, and Government, accounting for $1.90 billion.
Palantir Technologies, a leader in data integration and analytics, has recently raised its full-year revenue guidance to $4.15 billion, marking a substantial 45% year-over-year growth. This adjustment reflects robust U.S. commercial revenue projections, anticipated to surpass $1.3 billion—an 85% increase—demonstrating strong market demand and strategic positioning within the tech sector. In alignment with this growth trajectory, Palantir’s commitment to innovation is evident in its R&D investments which have been pivotal in developing advanced AI-driven platforms for diverse federal and commercial applications. These strategic moves not only enhance Palantir’s service offerings but also solidify its role in shaping future tech landscapes by addressing complex data challenges across various industries.
PLTR Earnings and Revenue Growth as at Aug 2025
Simply Wall St Growth Rating: ★★★★★☆
Overview: ServiceNow, Inc. offers cloud-based solutions for digital workflows across various regions globally and has a market capitalization of $181.06 billion.
Operations: The company generates revenue primarily from its Internet Software & Services segment, amounting to $12.06 billion.
ServiceNow’s recent strategic partnerships and product integrations, such as with TechSee and Staffbase, underscore its commitment to enhancing enterprise workflows through its AI Platform. These collaborations not only expand ServiceNow’s ecosystem but also integrate sophisticated AI tools directly into client operations, improving efficiency and user engagement. Notably, the company has also been proactive in share repurchases, buying back shares worth $360.96 million in Q2 2025 alone, reflecting confidence in its financial health and future prospects. Moreover, ServiceNow’s innovative approach is evident in its agentic workforce management solutions that significantly automate IT operations and customer support processes—demonstrating a robust integration of AI across enterprise levels which is set to redefine productivity standards within the tech industry.
NOW Revenue and Expenses Breakdown as at Aug 2025
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include PTGX PLTR and NOW.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
